1. Home
  2. PRLD vs NVFY Comparison

PRLD vs NVFY Comparison

Compare PRLD & NVFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • NVFY
  • Stock Information
  • Founded
  • PRLD 2016
  • NVFY 2003
  • Country
  • PRLD United States
  • NVFY United States
  • Employees
  • PRLD N/A
  • NVFY N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • NVFY Home Furnishings
  • Sector
  • PRLD Health Care
  • NVFY Consumer Discretionary
  • Exchange
  • PRLD Nasdaq
  • NVFY Nasdaq
  • Market Cap
  • PRLD 44.0M
  • NVFY 36.8M
  • IPO Year
  • PRLD 2020
  • NVFY N/A
  • Fundamental
  • Price
  • PRLD $1.03
  • NVFY $5.10
  • Analyst Decision
  • PRLD Strong Buy
  • NVFY
  • Analyst Count
  • PRLD 3
  • NVFY 0
  • Target Price
  • PRLD $4.00
  • NVFY N/A
  • AVG Volume (30 Days)
  • PRLD 231.3K
  • NVFY 1.8M
  • Earning Date
  • PRLD 11-05-2025
  • NVFY 11-13-2025
  • Dividend Yield
  • PRLD N/A
  • NVFY N/A
  • EPS Growth
  • PRLD N/A
  • NVFY N/A
  • EPS
  • PRLD N/A
  • NVFY N/A
  • Revenue
  • PRLD $7,000,000.00
  • NVFY $9,813,990.00
  • Revenue This Year
  • PRLD N/A
  • NVFY N/A
  • Revenue Next Year
  • PRLD N/A
  • NVFY N/A
  • P/E Ratio
  • PRLD N/A
  • NVFY N/A
  • Revenue Growth
  • PRLD N/A
  • NVFY N/A
  • 52 Week Low
  • PRLD $0.61
  • NVFY $0.39
  • 52 Week High
  • PRLD $2.72
  • NVFY $5.93
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 45.61
  • NVFY 82.27
  • Support Level
  • PRLD $1.03
  • NVFY $4.90
  • Resistance Level
  • PRLD $1.26
  • NVFY $5.39
  • Average True Range (ATR)
  • PRLD 0.11
  • NVFY 0.60
  • MACD
  • PRLD -0.03
  • NVFY 0.17
  • Stochastic Oscillator
  • PRLD 10.34
  • NVFY 79.91

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About NVFY Nova Lifestyle Inc.

Nova Lifestyle Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.

Share on Social Networks: